Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AUTO3

Cell therapy (CAR-T) · Kills target cells, directed at CD19 and CD22 · developed by Autolus

Phase 1/2 Most advanced trial (none active)

AUTL Developer

2 Registered trials

What is AUTO3?

AUTO3 is a CD19/CD22-directed chimeric antigen receptor (CAR) T-cell therapy, made from the patient's own T cells engineered to express CD19 and CD22 chimeric antigen receptors. It is studied in relapsed or refractory diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia, given after preconditioning with cyclophosphamide and fludarabine and with a limited course of pembrolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Targets: CD19 (antigen), CD22 (antigen)
Mechanism: Kills target cells, directed at CD19 and CD22
Therapy area: Oncology
Developer: Autolus Limited (AUTL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03287817	Phase 1/2	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Terminated	AUTL
NCT03289455	Phase 1/2	B Acute Lymphoblastic Leukemia	Completed	AUTL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic LeukemiaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Other drugs acting on CD19 / CD22

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 Epratuzumab-cys-tesirine Phase 1/2 MK-1045 Phase 2/3

More from Autolus

Obecabtagene autoleucel FDA approved AUTO2 Phase 1/2 AUTO4 Phase 1/2

Sources

ClinicalTrials.gov NCT03287817

Updated Oct 11, 2026. Something wrong or missing? Report it on the AUTL page.

Follow AUTL, the company behind AUTO3

See AUTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AUTL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z